目的 研究生血寧片聯(lián)合蛋白琥珀酸鐵口服溶液治療妊娠期缺鐵性貧血的臨床療效。方法 選取2018年6月—2019年6月在天津市寶坻區(qū)人民醫(yī)院治療的67例妊娠期缺鐵性貧血患者，將所有患者隨機分為對照組（34例）和治療組（33例）。對照組患者飯前口服蛋白琥珀酸鐵口服溶液，1瓶/次，2次/d。治療組在對照組基礎(chǔ)上口服生血寧片，2片/次，3次/d。兩組患者接受4周治療。觀察兩組的臨床療效，比較兩組血液學指標、鐵代謝指標、貧血發(fā)生率、早產(chǎn)率和產(chǎn)后出血率。結(jié)果 治療后，對照組和治療組的總有效率分別為76.47%、93.94%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組血清鐵（SI）、轉(zhuǎn)鐵蛋白飽和度（TSAT）顯著升高（P<0.05），且治療組SI、TSAT明顯高于對照組（P<0.05）。治療后，兩組患者血紅蛋白（Hb）、紅細胞計數(shù)（RBC）、平均紅細胞體積（MCV）、平均血紅蛋白濃度（MCHC）均顯著升高（P<0.05）；且治療組Hb、RBC、MCV、MCHC均高于對照組（P<0.05）。治療后，治療患者貧血發(fā)生率、早產(chǎn)率、產(chǎn)后出血率明顯低于對照組（P<0.05）。結(jié)論 生血寧片聯(lián)合蛋白琥珀酸鐵口服溶液治療妊娠期缺鐵性貧血具有較好的臨床療效，能夠改善血液學指標和鐵代謝指標，降低貧血發(fā)生率、早產(chǎn)率、產(chǎn)后出血率，值得在臨床上推廣應用。

Objective To evaluate the efficacy of Shengxuening Tablets combined with Iron Proteinsuccinylate Oral Solution in treatment of iron deficiency anemia during pregnancy. Methods Patients (67 cases) with iron deficiency in Baodi District People’s Hospital of Tianjin from June 2018 to June 2019 were randomly divided into the control group (34 cases) and the treatment group (33 cases). Patients in the control group were po administered with Iron Proteinsuccinylate Oral Solution before meals, 1 bottle /time, twice daily. Patients in the treatment group were po administered with Shengxuening Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and hematology indexes, iron metabolism indexes, the incidence of anemia, premature delivery and postpartum hemorrhage in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.47% and 93.94%, respectively, and there was difference between two groups (P<0.05). After treatment, SI and TSAT of the two groups were significantly increased (P<0.05), and the SI and TSAT of the treatment group were significantly higher than those of the control group (P<0.05). After treatment, Hb, RBC, MCV, and MCHC of the two groups were significantly increased (P<0.05), and Hb, RBC, MCV, and MCHC in the treatment group were higher than those in the control group (P<0.05). After treatment, the incidence of anemia, premature delivery, and postpartum hemorrhage in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shengxuening Tablets combined with Iron Proteinsuccinylate Oral Solution has clinical curative effect in treatment of iron deficiency anemia during pregnancy, can improve hematological indexes and iron metabolism indexes, reduce the incidence of anemia, premature delivery rate and postpartum hemorrhage rate, which is worthy of clinical application.

R973；R984